News
The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...
Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...
In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth ...
Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...
A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the FDA’s crosshairs for the second time in less than a year. | The FDA has ...
Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...
Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...
What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...
Eli Lilly experienced a 16% price increase last week, potentially benefiting from two major developments. The company's collaboration with BigHat Biosciences utilizes advanced technology to ...
Eli Lilly stocks displayed a major rise after the announcement of a new oral weight-loss drug that has put pressure on its rival pharmaceutical companies Eli Lilly’s stock surged 16% after the ...
Learn More » Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly (NYSE: LLY). But now, an investment in Lilly may not look so enticing as the possibility of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results